Evidence map›Paper›PMID 40739689›Full record

SynthesisCNS & neurological disorders drug targets2026

Neurosarcoidosis - Epidemiological, Clinical, Diagnostic, and Therapeutic Aspects: A Systematic Review.

Jamily Izabel Alves Dos Santos, Valeria Dos Santos Turbano, Ana Tercia Mendes Carneiro, Bruno Farias Oliveira, Lucas Gregorio Batista, Argemiro Erick Landim Grangeiro, Pedro Joabe de Assis Silva, Alyne Layane Pereira Lemos, Gislene Farias de Oliveira, Hermes Melo Teixeira Batista and 2 more

Abstract readSystematic Review
PubMed Publisher
In one paragraph

Synthesis in CNS & neurological disorders drug targets, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jamily Izabel Alves Dos SantosSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Valeria Dos Santos TurbanoSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Ana Tercia Mendes CarneiroSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Bruno Farias OliveiraSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Lucas Gregorio BatistaSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Argemiro Erick Landim GrangeiroSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Pedro Joabe de Assis SilvaSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Alyne Layane Pereira LemosSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Gislene Farias de OliveiraSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Hermes Melo Teixeira BatistaSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Marco Felipe Macedo AlvesSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.
Jucier Goncalves JuniorSchool of Medicine, Federal University of Cariri, Juazeiro do Norte, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeurosarcoidosis is a rare and severe manifestation of sarcoidosis, whose natural history still lacks a comprehensive and theoretical understanding. Therefore, we aimed to conduct a qualitative systematic review of the literature on the clinical-epidemiologic, diagnostic, and therapeutic assessment of patients with neurosarcoidosis.

methodsA qualitative systematic literature review was conducted in accordance with the PRISMA protocol. The search was conducted between January 1954 and December 2024 in the following databases: PubMed, Scopus, Web of Science, CAPES Journal Portal, and the Virtual Health Library (VHL). Articles were selected if they had at least one of the selected descriptors in the title or abstract, were written in English, Portuguese, or Spanish, and dealt with the clinical-epidemiologic, diagnostic, and therapeutic aspects of neurosarcoidosis. Review articles, experimental studies, and short communications were excluded from the analysis.

resultsSeventy-four articles with 551 cases of neurosarcoidosis were included. The majority of studies were case reports, followed by cohort studies conducted in European countries. The methodological quality of most studies was "good". DISCUSSION: Patients with neurosarcoidosis are primarily women Caucasian ethnicity with a mean age of 43.5 years. The disease most commonly involves the cranial nerves (especially cranial nerve II), followed by aseptic meningitis, panhypopituitarism, ocular changes, and diabetes insipidus. The most common laboratory findings were cerebrospinal fluid abnormalities, hypogonadotropic hypogonadism, hyperprolactinemia, and hypothyroidism. The most common neuroimaging changes were meningeal enhancement and pituitary destruction. The treatment of choice was glucocorticoids in conjunction with or without immunosuppressants, with methotrexate and azathioprine being the most commonly used.

conclusionThis review identified that manifestations such as cranial nerve alterations, aseptic meningitis, and pituitary infiltrations are frequent patterns in neurosarcoidosis, generally associated with laboratory and imaging findings that aid in the diagnosis. Systematizing these data provides a broad view of the disease and may contribute to early diagnosis and effective therapy. Nevertheless, longitudinal studies with larger samples are needed to better understand its natural history and clinical outcomes in the medium and long term.

Indexed as

Central Nervous System DiseasesSarcoidosisHumansCentral nervous system diseasesneurosarcoidosispituitary glandsarcoidosissystematic reviewtreatment.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.